Lymphocyte depletion after alemtuzumab treatment in patients with myelodysplastic syndrome. Absolute lymphocyte counts (cells/μL) from complete blood counts in patients at 0, 1, 3, 6, 12, and 24 months after the first dose of alemtuzumab. Each value represents the mean ± SE for all evaluable patients.